ARA Avanti Rx Analytics



March 27, 2018

Aphria Launches Aphria International And Provides Updates On Worldwide Operations

Recently-acquired Nuuvera to be renamed Aphria International. Aphria International will focus on expanding the Company’s footprint in established regulated cannabis markets outside of Canada.

Leamington, Ontario – March 27, 2018 – Aphria Inc. (“Aphria” or the “Company”) (TSX: APH and US OTC: APHQF) is pleased to provide the following updates to the Company’s worldwide operations and activities.


  • Nuuvera Inc. will be renamed Aphria International Inc. (“Aphria International”) and remain a wholly-owned subsidiary of Aphria.

  • Aphria International will focus on existing and future opportunities in established regulated international cannabis markets including, but not limited to, Germany, Italy, Spain, Portugal, Malta, Australia and Lesotho.

  • In Canada, Aphria will assume management of Nuuvera’s Canadian assets, including ARA-Avanti RX Analytics Inc. (“Avanti”), the only Canadian cannabis GMP-certified lab, and existing relationships and supply agreements in the Maritimes.

“Today, Aphria is affirming its place as a global leader in medical cannabis, with the resources and vision for sustained growth in markets around the world,” said Vic Neufeld, CEO of Aphria. “We’re excited to unite under one name Aphria’s unparalleled ability to grow low-cost, high-quality cannabis at scale with Nuuvera’s expansive international network, expertise and access to established medical cannabis markets. We’ve also strengthened our Canadian operations with access to the Maritimes, the addition of the cannabis GMP-certified Avanti lab, and reclaimed value from the offtake agreements previously in place with Nuuvera. All told, this deal has potential to create significant and long-term value for all Aphria shareholders.”.......Read More


January 29, 2018

Aphria to Buy Nuuvera for $826 Million in Cash and Stock

Global leader in medical cannabis created by Aphria and Nuuvera combination
LEAMINGTON, ON and TORONTO, Jan. 29, 2018 /CNW/ – Global leader in medical cannabis created by Aphria and Nuuvera combination LEAMINGTON, ON and TORONTO, Jan. 29, 2018 /CNW/ – Aphria Inc. (“Aphria” or the “Company”) (TSX: APH and US OTC: APHQF) and Nuuvera Inc. (“Nuuvera”) (TSXV:NUU), a leading, global cannabis company with a strong presence in Europe, Africa and the Middle East, are pleased to announce that they have entered into a definitive arrangement agreement (the “Arrangement Agreement”) pursuant to which Aphria will acquire, by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Transaction”) 100% of the issued and outstanding common shares (on a fully-diluted basis) of Nuuvera. The combined company will leverage Nuuvera’s extensive international network and best-in-class manufacturing practices to become the preeminent global supplier of premium cannabis. The acquisition brings an already successful partnership between Aphria and Nuuvera under the Aphria brand, reducing costs and providing the potential to unlock greater economic value from future production. The Transaction has been unanimously approved by the Board of Directors of each of Aphria and Nuuvera and is supported by the management teams of both companies as well as significant shareholders of Nuuvera. The Transaction values Nuuvera at approximately $826 million.

Transaction Rationale

Creates the Global Leader in the International Medical Cannabis Market: Aphria will leverage Nuuvera’s numerous relationships in Germany, Italy, Spain, the United Kingdom, Malta, Israel, Lesotho and Uruguay. Combined with Aphria’s existing agreements in Australia, the combined company establishes a leading international footprint among Canadian licensed producers, and expands Aphria’s processing and manufacturing capabilities globally........Read More


January 09, 2018

Nuuvera shortlisted for cannabis contract with the German Federal Institute for Drugs and Medical Devices

TORONTO, Jan. 9, 2018 /CNW/ - Nuuvera Inc. ("Nuuvera") (TSXV: NUU) has been shortlisted by the German Federal Institute for Drugs and Medical Devices (BfArM) for a contract to grow, process, store and deliver up to 6000 kg of cannabis in Germany.

Over 100 interested undertakings answered BfArM's initial call for competition. Nuuvera is one of 10 remaining bidders asked to submit an offer in the public procurement procedure.

Lorne Abony, CEO of Nuuvera Inc. stated, "We are tremendously excited about BfArM's decision, and for the headway Nuuvera has made in Germany, which is one of the largest markets in the world to legalize cannabis for medical usage.".......Read More


January 09, 2018

Nuuvera Germany breaks ground on facility for storage and packaging of medical cannabis

TORONTO, Jan. 9, 2018 /CNW/ - Nuuvera Deutschland GmbH, a wholly-owned subsidiary of Nuuvera Inc. ("Nuuvera") (TSXV: NUU), announced today that it has broken ground on the construction of a storage and packaging facility for medical cannabis products.

Nuuvera recently purchased a 11,300 square-foot property in Bad Bramstedt, in northern Germany, to build a premium vault storage system equipped with state-of-the-art security and related technology. The facility is expected to meet the most stringent requirements for the storage of controlled substances in Germany and the EU.

Lorne Abony, the CEO of Nuuvera, said that the new facility will ensure the company can continue to develop into a major supplier of medical cannabis products to German consumers........Read More


January 09, 2018

Nuuvera enters into letter of intent to export 1,200 kilograms of medical cannabis to Germany

TORONTO, Jan. 9, 2018 /CNW/ - Today Nuuvera Inc. ("Nuuvera") (TSXV: NUU) announced that it has entered into a letter of intent ("LOI") with German pharmaceutical company CC Pharma GmbH to export approximately 1,200 kilograms of medical cannabis products from Canada to Germany.

Under the terms of the LOI, CC Pharma, a leading distributor of pharmaceutical products to over 13,000 pharmacies in Germany, has agreed to import approximately 1,200 kilograms of medical cannabis from Nuuvera in 2018. The completion of the transaction is subject to and conditional upon the execution of the definitive agreement, the approval from the TSX Venture Exchange, and the approval of the relevant Canadian and German governmental authorities.

Lorne Abony, the CEO of Nuuvera, said the agreement will bring together two companies with a strong commitment to high standards of quality and consistency........Read More


January 07, 2018

Nuuvera to List on TSX Venture Exchange Tuesday January 9th

TORONTO, Jan. 7, 2018 /CNW/ - Due to a clerical error at the TSX, Nuuvera Inc. ("Nuuvera") (TSXV : NUU) was advised by the TSX this morning that it will be open for trading at the market open ‪on Tuesday, January 9, 2018, and not ‪on Monday, January 8, 2018, as previously announced. Nuuvera has been assured by the TSX that the 24-hour delay has been solely caused by the TSX itself and in no way reflects any change in Nuuvera's status as a listed issuer on the TSX Venture Exchange in good standing.

In connection with the trading delay, Ungad Chadda, President, Capital Formation, Toronto Stock Exchange, TSX Venture Exchange, provided the following statement to Nuuvera and its shareholders:

"We are honoured to have Nuuvera join the TSX Venture Exchange and want to assure the public that Nuuvera has been formally approved as a listed company on the TSX Venture Exchange. We also take this opportunity to apologize to Nuuvera and its stakeholders on the delayed first day of trading which was caused by a clerical error. Nuuvera will be available for trading at the open on Tuesday, January 9, 2018, and we look forward to hosting the Nuuvera team to open the market this Wednesday, January 10, 2018 to celebrate their listing.".......Read More


October 10, 2017

Medical Marijuana Is About To Become More Accessible In Malta

Joseph Muscat says updated law will allow production of medical marijuana in Malta

Malta’s law regulating medical marijuana is about to become less restricted, Prime Minister Joseph Muscat has announced.

“Cabinet will start discussing changes to the law regulating medical marijuana in November,” Muscat told a media briefing yesterday. “It is only when we update the law on medical marijuana that we’ll start discussing possible legalisation for personal use.”........Read More


October 06, 2017

Nuuvera Corp. and Mira IX Acquisition Corp. Announce Going Public Qualifying Transaction

TORONTO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Mira IX Acquisition Corp. (“Mira IX”) (TSXV:MIA.P) is pleased to announce that it has entered into a letter of intent dated October 6, 2017 with Nuuvera Corp. (“Nuuvera”) to complete a going-public transaction in Canada for Nuuvera (the “Proposed Transaction”). Mira IX intends that the Proposed Transaction will constitute its “Qualifying Transaction” under Policy 2.4 - Capital Pool Companies of the TSX Venture Exchange (the “TSXV”). For convenience, Mira IX, as it will exist after completion of the Proposed Transaction, is sometimes referred to herein as the “Resulting Issuer”.

Nuuvera is engaged in the testing, formulation, production, extraction and sale of medicinal cannabis products in Canada and other legal International jurisdictions (excluding the United States, where no Nuuvera business is conducted). Nuuvera carries on its business through its subsidiaries, ARA-Avanti Rx Analytics Inc. (“Avanti”), of which Nuuvera indirectly holds 51%, and Avalon Pharmaceuticals Inc. (“Avalon”), an indirect, wholly-owned subsidiary of Nuuvera.

Avanti is a “Licensed Dealer” as defined pursuant to the Narcotic Control Regulations and holds an establishment license evidencing its facility’s compliance with Health Canada’s Good Manufacturing Practices requirements. The business of Avanti is the extraction, testing and analysis of cannabis and cannabis derivative products on behalf of “Licensed Producers” and other authorized individuals under the Narcotic Control Regulations and the Access to Cannabis for Medical Purposes Regulations. Avanti does not grow, distribute, nor sell/commercialize cannabis. In addition, Avanti offers a comprehensive menu of services in respect of controlled substances beyond cannabis including analytical research and development and quality control, as well as quality assurance and regulatory consulting........Read More


May 10, 2017

Delivra Signs Exclusive Licensing Deal with ARA-Avanti Rx Analytics for Hemp Non-Psychoactive Cannabinoid, Terpene and Flavonoid Formulations and Products

TORONTO, ON--(Marketwired - May 10, 2017) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") and ARA-Avanti Rx Analytics Inc. ("Avanti") announced today a strategic partnership to develop a unique suite of standardized natural and medicinal products for the medical pain-related research, development, and commercialization markets, using hemp.

The hemp plant has been hugely overlooked as a great alternative for pain management and other medical conditions. The partnership between the two companies addresses many of the concerns of the unsettling psychotropic effects of THC found in cannabis, especially in the elderly and high anxiety patient population. In comparison, hemp contains low THC cannabis content and many beneficial cannabinoids, including cannabidiol (CBD). Hemp is also known for its diverse and robust anti-inflammatory flavonoids content, along with its high nutritional value because of its high essential polyunsaturated fatty acids (omega 3's), which matches that of the human body. Properly administered, medical non-psychotropic cannabis provides real alternatives to more addictive type drugs, including opioids........Read More


April 20, 2017

Canadian company working on topical cream containing medical marijuana

Canadian medical marijuana patients could soon find themselves ditching the pipe, bong or vaporizer for a topical cream or an oral spray that contains the active ingredients of cannabis, according to the CEO of biotechnology company Delivra Corp. .......Read More


April 19, 2017

Algae Dynamics Corp Announces Joint Venture with ARA - Avanti Rx Analytics Inc. to Formulate, Manufacture and Sell Products Utilizing Algae, Hemp & Cannabis Oils

TORONTO, ON--April 19, 2017 ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the "Company" or “ADC”), a company focused on the development of unique health products and pharmaceuticals utilizing cannabis, hemp and algae oils today announced a joint venture with ARA - Avanti Rx Analytics Inc. (“ARA”) in a newly-formed subsidiary entity called ADC Biomedical Corp (“BIO”), the equity of which will be owned 4% and 96% by ARA and ADC, respectively. Previously, the Company had announced a memorandum of understanding with ARA with respect to strategic collaboration between the two companies. This announcement is an extension of that previously-announced collaboration.

It is the intention of the joint venture for BIO to be the preferred purchaser from ARA of all BIO’s and ADC’s products containing algae, hemp oil, and cannabis extracted oils, and/or their compounds. ADC will be responsible for the provision of raw materials, or if required by law, will arrange for the provision of raw materials to ARA for processing. ARA will be responsible for processing the raw materials into finished bulk goods and/or packaged products, and shipping same to BIO’s licensed clients/sellers and research organizations. ARA will process materials according to agreed prices and specifications, which may be modified from time to time. The initial term of the joint venture is for three (3) years, effective April 10, 2017, renewing automatically unless notice is given from one party to the other to terminate. In addition, the joint venture may be terminated upon the occurrence of a material breach that remains uncured for 60 days.” .......Read More


April 18, 2017

ICC Enters into Importation Agreement with ARA – Avanti Rx Analytics

Vancouver, British Columbia, Tuesday, April 18, 2017 - ICC International Cannabis Corporation (“ICC” or the “Company”) (TSXV: ICC) is pleased to announce that it has entered into an Importation Agreement with ARA – Avanti Rx Analytics Inc. (“Avanti”), a licensed dealer under the Controlled Drugs and Substances Act (Canada) and its regulations overseen by Health Canada.

“We are pleased to enter into the Importation Agreement with Avanti with a view to working together to provide Canadians with a broader supply of cannabidiol (“CBD”) oil and cannabis extract oils, and other related products from our Uruguayan operations at competitive price points,” commented Guillermo Delmonte, Chief Executive Officer of ICC. “In addition, Avanti brings to the table extensive knowledge and expertise in the field of quality control, cannabis extraction, and CBD purification. The business relationship with Avanti is expected to allow ICC to leverage Avanti’s dealer license and laboratory facilities in order to facilitate sales in Canada, and represents a positive next step in ICC’s strategy to export to global markets where lawful.” .......Read More


April 12, 2017

Cura-Can Health Enters Into Services Agreement With ARA-Avanti Rx

TORONTO, ONTARIO--(Marketwired - April 12, 2017) - Cura-Can Health Corp.("Cura-Can" or the "Company") a private, federally incorporated company, is pleased to announce that its wholly-owned subsidiary, The Clinic Network Canada Inc. ("TCNC"), has entered into a services agreement with ARA-Avanti Rx Analytics Inc. (the "Avanti") pursuant to which Avanti has agreed to produce cannabidiol ("CBD") based products, for both medicinal and supplement applications, for sale by TCNC directly to medical patients and non-medical clients, through its Cura "SELECT" house brand (the "Services Agreement").

Avanti is a leading Health Canada approved contract organization specializing in the field of controlled drugs and substances particularly in the area of medicinal marihuana, hemp, cannabinoids, and marihuana based concentrated products. Avanti offers a comprehensive menu of services ranging from analytical research and development, and quality control testing, marihuana extraction, cannabinoid purification, cannabis infused-product formulation, and cannabis waste management, as well as quality assessment and regulatory consulting. .......Read More


March 21, 2017

Delivra Signs Exclusive Licensing Deal with Dosecann for Cannabis Oil Formulations in Metered Dose Formats

March 21, 2017 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”), Dosecann Inc. (“Dosecann”) and ARA-Avanti Rx Analytics Inc. (“Avanti”) announced today a strategic partnership to develop a unique suite of standardized products for the medical cannabis research, development, and commercialization markets.

“The Federal Government of Canada has numerous concerns, and barriers to overcome, before legalizing cannabis, including stricter regulatory controls. The partnership between the three companies addresses many of these concerns, providing greater safety and efficacy of medical cannabis specific products for the patient, with products that provide consistent, accurate dosing, and that are manufactured under pharmaceutical GMP Standards,” said Dr. Joseph Gabriele, CEO of Delivra. “This collaboration between Delivra, Dosecann and Avanti addresses an exploding field of medicine by seeking to standardize, validate, package and distribute cannabis products in innovative mono-dose delivery platforms to licensed producers and other future legal distribution networks, ultimately meeting the needs of the patient.” .......Read More


March 16, 2017

Algae Dynamics Corp Announces Memorandum of Understanding with Company Licenced by Health Canada to Test, Extract, Purify, Import/ Export and Sell Cannabis Oil

TORONTO, CANADA / March 16, 2017, 9:30 AM EDT/ ALGAE DYNAMICS CORP (OTCQB: ADYNF)(the "Company" or “ADC”), a development stage company focused on the development of unique health products and pharmaceuticals utilizing cannabis and algae oils, today announced a memorandum of understanding with Avanti Rx Analytics Inc. (“ARA”) to collaborate on a range of topics as outlined below. ARA is uniquely positioned to test, extract, develop, produce and supply cannabinoids that can enable and enhance the delivery and commercial success of medicinal cannabis products. As such, ARA will play a key role in supplying the University of Waterloo and Western University with cannabis oil for the previously announced sponsored research programs, in addition to contributing to the product development and formulation opportunities that combine the benefits of algae and cannabis oils.

Paul Ramsay, Chairman and President of the Company said, “This collaboration is a vital piece of our corporate development strategy. Our relationship with ARA will assist us immensely in the development of unique products both in the medical cannabis category, as well as in unique formulations utilizing cannabis and algae oils. It dove-tails beautifully with our recently announced research relationships with two universities, and we believe will help fast-track us to revenue.” .......Read More


December 12, 2016

The Daily Marijuana Observer - Canada Licensed Dealers List

According to a Government of Canada website, the following is a list of laboratories that have a current Dealers License under the Narcotic Control Regulations and who are licensed to conduct special activities with cannabis. .......Read More


Elemental Impurities: new USP chapters <232>, <233>, and <2232>

Drug products and dietary supplements for the US market will soon have to comply with the new elemental impurities requirements and testing set forth by the USP General Chapters <232> Elemental Impurities—Limits, <233> Elemental Impurities—Procedures, and <2232> Elemental Contaminants in Dietary Supplements. The USP recognized that the current chapter <231> Heavy Metals was obsolete, and it will be eliminated completely on 1/1/2018, when also the new chapters will be officially implemented.

These new chapters include the use of modern procedures and analytical equipment, and establish the limits for acceptable levels of elemental impurities in drug products and dietary supplements. These changes will affect not just the drug manufacturers but also the raw materials supplier for active pharmaceutical ingredients (APIs) and/or excipients